Form 4: Director Ngar Yee Louie Buys MAIA Stock & Options

MAIA Biotechnology Director Ngar Yee Louie acquired common stock and stock options on December 22, 2025, increasing her beneficial ownership.

Summary

• Director Ngar Yee Louie of MAIA Biotechnology, Inc. (MAIA) acquired common stock and stock options on December 22, 2025.
• The transaction involved the purchase of 81,699 shares of common stock at a price of $1.224 per share.
• Following this transaction, Director Louie's direct beneficial ownership of common stock increased to 1,248,888 shares.
• Additionally, 81,699 stock options (deemed warrants) were acquired with an exercise price of $1.36.
• These stock options become exercisable on June 22, 2026, and are set to expire on December 22, 2028.
• Both the common stock and stock options were purchased pursuant to a Securities Purchase Agreement and issued under the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The director's purchase of common stock and stock options is a positive signal, indicating confidence in the company's future performance and aligning their interests with shareholders.

Positives

• Director Ngar Yee Louie increased her direct beneficial ownership in MAIA Biotechnology, indicating confidence in the company's future prospects.
• The acquisition of both common stock and stock options aligns the director's financial interests more closely with those of the company's shareholders.

Future Outlook

This Form 4 filing is a transaction report and does not contain any forward-looking statements or guidance from MAIA Biotechnology, Inc. regarding its future performance or strategic direction.

Industry Context

Insider purchases, particularly by a director, are often interpreted as a positive signal within the biotechnology industry, suggesting that those closest to the company believe in its future prospects. This can be especially relevant in a sector known for its high-risk, high-reward nature, where management confidence can influence investor sentiment.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4) and is a common disclosure across all industries when directors or officers acquire or dispose of company securities.
• The act of a director purchasing company stock and options is generally viewed as a positive indicator, aligning with best practices for corporate governance where management's interests are tied to shareholder value.
• No specific comparable companies, projects, or results are mentioned in the filing to allow for a detailed comparative assessment of the transaction's financial implications against industry benchmarks.

Related Party Transactions

• Director Ngar Yee Louie acquired common stock and stock options from MAIA Biotechnology, Inc. pursuant to a Securities Purchase Agreement and the Issuer's 2021 Equity Incentive Plan. This constitutes a related party transaction as it involves a company director.

Stakeholder Impact

• Shareholders: The insider buying by a director could be perceived as a positive signal, potentially boosting investor confidence and sentiment regarding the company's future outlook.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is explicitly mentioned or implied by this insider transaction report.

Key Dates

Recommendation

The director's acquisition of common stock and stock options signals confidence in MAIA Biotechnology's future. This insider buying activity is generally viewed favorably by the market, suggesting that the director believes the stock is undervalued or has significant upside potential. However, a Form 4 filing alone does not provide sufficient comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation without further due diligence. It serves as a positive indicator for existing shareholders to hold and for potential investors to conduct deeper analysis.

Keywords

MAIA Biotechnology, MAIA, Insider Trading, Form 4, Director Stock Purchase, Stock Options, Equity Incentive Plan, Securities Purchase Agreement